| Name | Title | Contact Details |
|---|
At PharmMD, we believe every patient deserves personalized attention, the best information available, and reliable guidance from medical professionals to live a healthier life. This deeply held conviction guided our founder Fred McWhorter, an old-fashioned pharmacist who devoted more than 50 years to his passion of bringing health and healing to his customers–not simply selling medicine. Recognizing the value of emerging technology, he envisioned building a real-time information bridge between pharmacists (Pharm) and physicians (MD) to significantly improve patient treatment. Following Fred’s untimely death in 2005, his brother Clayton McWhorter, a veteran healthcare pioneer, brought Fred’s dream to fruition. In 2006, Clayton teamed with entrepreneur Samuel “Bo” Bartholomew to establish PharmMD in Nashville, TN. With the arrival of successful healthcare executive Robert Yeager as CEO in 2013, PharmMD pressed to the forefront in Medicare Part D Star Ratings improvement, as well as Medication Therapy Management (MTM) programs. Today PharmMD remains a leader in quality improvement and a healthcare industry innovator, delivering fast and effective solutions to CMS-regulated health plans and employer groups. Our pioneering technology, proprietary protocols and personalized patient profiles, combined with our outcomes-driven reporting, provide a catalyst for effective medication decisions; ultimately upholding Fred’s vision for improving lives. We exist to create a healthier world through the most effective use of the right medication.
Forest Labs is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Supreme Cannabis Company (TSXV: FIRE) (OTCQX: SPRWF) (FRA: 53S1) is a Canadian publicly traded company committed to providing premium brands and products that proudly reflect its consumers, people and uniquely innovative culture. The Company`s portfolio includes its wholly-owned subsidiary and award-winning brand, 7ACRES. 7ACRES is a federally licensed producer of cannabis operating inside a 342,000-square-foot facility in Kincardine, Ontario. 7ACRES is dedicated to providing consumers with a premium-quality product that recognizes its customers are informed, discerning and value a brand and culture that aligns with their principles. 7ACRES brand success has been reflected in its "Brand of the Year" award win at the 2018 Canadian Cannabis Awards, and in provincial supply agreements where 7ACRES` product is consistently listed in the highest brand category available to recreational consumers. The Company`s growing portfolio also includes an equity investment and long-term global distribution partnership with Lesotho-based Medigrow for the exporting of medical-grade cannabis oil. The Supreme Cannabis Company has been a leading innovator in the sector including the design of growing facilities and development of operational excellence metrics. We are confident that together with our flagship brand, proprietary technology and products, truly unique culture, and industry-leading team, we will deliver our shareholders consistent long-term value creation.
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.